English

Aquestive Therapeutics, Inc.

EDGAR

AQST Current report (8-K) · filed 2026-10-19

Annual consolidated revenue for 2025: about USD 44.55M, using the latest reported figures. The previous period, 2024, was about USD 57.56M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

13.8 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 13819000 USD Source

Operating margin

-59.51%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -8223000 USD Source
Revenue: 13819000 USD Source

Operating cash flow

-9.44 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -24247000 USD Source
Operating Cash Flow: -14806000 USD Source

Free cash flow

-9.65 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -24247000 USD Source
Operating Cash Flow: -14806000 USD Source
Capital Expenditure: 264000 USD Source
Capital Expenditure: 52000 USD Source

Cash and cash equivalents: 98.5 million USD 2026-06-30 Source
Exact value

98490000 USD
Long-term debt including current maturities: 55 million USD 2026-06-30 Source
Exact value

55000000 USD
Shares outstanding: 126 million shares 2026-06-30 Source
Exact value

125511648 shares

Reported share-count change

26.33% · 26.2 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

99353270 shares · 2025-06-30· Source
125511648 shares · 2026-06-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-19.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2025-12-31
Operating income: 6 of 11 periods available· newest 2025-12-31
Net income: 6 of 11 periods available· newest 2025-12-31
Operating cash flow: 6 of 11 periods available· newest 2025-12-31
Capital expenditure: 6 of 11 periods available· newest 2025-12-31
Total assets: 6 of 11 periods available· newest 2025-12-31
Total liabilities: 6 of 11 periods available· newest 2025-12-31
Current assets: 6 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 3 of 11 periods available· newest 2025-12-31
Shares outstanding: 6 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-22.6%

Prior period

USD 57.56 million

2024-01-01 – 2024-12-31
Current period

USD 44.55 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

44545000 − 57561000 = -13016000 USD

57561000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
44545000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Aquestive Therapeutics, Inc. · 2025-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Year-over-year change in Revenue: -13016000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 44545000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm#1543096 Filing: 000139873326000018 Input fundies:Revenue: 57561000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm#1544079 Filing: 000139873326000018
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 39.65 million

Prior period

−USD 44.14 million

2024-01-01 – 2024-12-31
Current period

−USD 83.78 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-83784000 − -44137000 = -39647000 USD

-44137000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-83784000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Aquestive Therapeutics, Inc. · 2025-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Year-over-year change in Net income: -39647000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -83784000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm#1808255 Filing: 000139873326000018 Input fundies:NetIncome: -44137000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm#1809028 Filing: 000139873326000018
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 16.67 million

Prior period

−USD 35.76 million

2024-01-01 – 2024-12-31
Current period

−USD 52.43 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-52432000 − -35759000 = -16673000 USD

-35759000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-52432000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Aquestive Therapeutics, Inc. · 2025-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Year-over-year change in Operating cash flow: -16673000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -52432000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm#1351039 Filing: 000139873326000018 Input fundies:OperatingCashFlow: -35759000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm#1351691 Filing: 000139873326000018
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+253.5%

Prior period

USD 159,000

2024-01-01 – 2024-12-31
Current period

USD 562,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

562000 − 159000 = 403000 USD

159000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
562000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Aquestive Therapeutics, Inc. · 2025-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Year-over-year change in Capital expenditure: 403000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 562000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm#1352994 Filing: 000139873326000018 Input fundies:CapitalExpenditure: 159000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm#1353553 Filing: 000139873326000018
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 44.55 million 100% of revenue
Cost of revenue USD 18.56 million 42% of revenue
Operating expenses USD 97.04 million 218% of revenue
Operating income −USD 71.05 million −160% of revenue
Tax, interest and other Derived USD 12.73 million 29% of revenue
Net income −USD 83.78 million −188% of revenue

Cash

Operating cash flow −USD 52.43 million −118% of revenue
Capital expenditure USD 562,000 1.3% of revenue
Free cash flow Derived −USD 52.99 million −119% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Operating loss: operating costs were 194% of revenue.
2021 Operating loss: operating costs were 168% of revenue.
2022 Operating loss: operating costs were 188% of revenue.
2023 Operating loss: operating costs were 130% of revenue.
2024 Operating loss: operating costs were 153% of revenue.
2025 Operating loss: operating costs were 260% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	45849000	88742000 Derived	-42893000	12890000 Derived	-55783000	-45976000 Derived	Source 2020-01-01 – 2020-12-31: 45849000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -42893000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -55783000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -45459000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 517000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	50832000	85511000 Derived	-34679000	35860000 Derived	-70539000	-33892000 Derived	Source 2021-01-01 – 2021-12-31: 50832000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -34679000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -70539000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -32979000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 913000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	47680000	89746000 Derived	-42066000	12344000 Derived	-54410000	-10843000 Derived	Source 2022-01-01 – 2022-12-31: 47680000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -42066000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -54410000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -9819000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 1024000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	50583000	65685000 Derived	-15102000	-7232000 Derived	-7870000	-7375000 Derived	Source 2023-01-01 – 2023-12-31: 50583000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -15102000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -7870000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -6380000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 995000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	57561000	88332000 Derived	-30771000	13366000 Derived	-44137000	-35918000 Derived	Source 2024-01-01 – 2024-12-31: 57561000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -30771000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -44137000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -35759000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 159000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	44545000	115596000 Derived	-71051000	12733000 Derived	-83784000	-52994000 Derived	Source 2025-01-01 – 2025-12-31: 44545000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -71051000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -83784000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -52432000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 562000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 44.5M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	45849000	Revenue: 45849000 Open source
20212021-12-31	Revenue	50832000	Revenue: 50832000 Open source
20222022-12-31	Revenue	47680000	Revenue: 47680000 Open source
20232023-12-31	Revenue	50583000	Revenue: 50583000 Open source
20242024-12-31	Revenue	57561000	Revenue: 57561000 Open source
20252025-12-31	Revenue	44545000	Revenue: 44545000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-22.6% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 45849000 Open source
20212021-12-31	Year over year	10.9%	Revenue: 50832000 Open source Revenue: 45849000 Open source
20222022-12-31	Year over year	-6.2%	Revenue: 47680000 Open source Revenue: 50832000 Open source
20232023-12-31	Year over year	6.1%	Revenue: 50583000 Open source Revenue: 47680000 Open source
20242024-12-31	Year over year	13.8%	Revenue: 57561000 Open source Revenue: 50583000 Open source
20252025-12-31	Year over year	-22.6%	Revenue: 44545000 Open source Revenue: 57561000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -159.5% 2025

Net margin -188.1% 2025

Free cash flow margin -119% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-93.6%	Operating Income: -42893000 Open source Revenue: 45849000 Open source
20212021-12-31	Operating margin	-68.2%	Operating Income: -34679000 Open source Revenue: 50832000 Open source
20222022-12-31	Operating margin	-88.2%	Operating Income: -42066000 Open source Revenue: 47680000 Open source
20232023-12-31	Operating margin	-29.9%	Operating Income: -15102000 Open source Revenue: 50583000 Open source
20242024-12-31	Operating margin	-53.5%	Operating Income: -30771000 Open source Revenue: 57561000 Open source
20252025-12-31	Operating margin	-159.5%	Operating Income: -71051000 Open source Revenue: 44545000 Open source
20202020-12-31	Net margin	-121.7%	Net Income: -55783000 Open source Revenue: 45849000 Open source
20212021-12-31	Net margin	-138.8%	Net Income: -70539000 Open source Revenue: 50832000 Open source
20222022-12-31	Net margin	-114.1%	Net Income: -54410000 Open source Revenue: 47680000 Open source
20232023-12-31	Net margin	-15.6%	Net Income: -7870000 Open source Revenue: 50583000 Open source
20242024-12-31	Net margin	-76.7%	Net Income: -44137000 Open source Revenue: 57561000 Open source
20252025-12-31	Net margin	-188.1%	Net Income: -83784000 Open source Revenue: 44545000 Open source
20202020-12-31	Free cash flow margin	-100.3%	Revenue: 45849000 Open source Operating Cash Flow: -45459000 Open source Capital Expenditure: 517000 Open source
20212021-12-31	Free cash flow margin	-66.7%	Revenue: 50832000 Open source Operating Cash Flow: -32979000 Open source Capital Expenditure: 913000 Open source
20222022-12-31	Free cash flow margin	-22.7%	Revenue: 47680000 Open source Operating Cash Flow: -9819000 Open source Capital Expenditure: 1024000 Open source
20232023-12-31	Free cash flow margin	-14.6%	Revenue: 50583000 Open source Operating Cash Flow: -6380000 Open source Capital Expenditure: 995000 Open source
20242024-12-31	Free cash flow margin	-62.4%	Revenue: 57561000 Open source Operating Cash Flow: -35759000 Open source Capital Expenditure: 159000 Open source
20252025-12-31	Free cash flow margin	-119%	Revenue: 44545000 Open source Operating Cash Flow: -52432000 Open source Capital Expenditure: 562000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -52.4M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-45459000	Operating Cash Flow: -45459000 Open source
20212021-12-31	Operating cash flow	-32979000	Operating Cash Flow: -32979000 Open source
20222022-12-31	Operating cash flow	-9819000	Operating Cash Flow: -9819000 Open source
20232023-12-31	Operating cash flow	-6380000	Operating Cash Flow: -6380000 Open source
20242024-12-31	Operating cash flow	-35759000	Operating Cash Flow: -35759000 Open source
20252025-12-31	Operating cash flow	-52432000	Operating Cash Flow: -52432000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -53M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-45976000	Operating Cash Flow: -45459000 Open source Capital Expenditure: 517000 Open source
20212021-12-31	Free cash flow	-33892000	Operating Cash Flow: -32979000 Open source Capital Expenditure: 913000 Open source
20222022-12-31	Free cash flow	-10843000	Operating Cash Flow: -9819000 Open source Capital Expenditure: 1024000 Open source
20232023-12-31	Free cash flow	-7375000	Operating Cash Flow: -6380000 Open source Capital Expenditure: 995000 Open source
20242024-12-31	Free cash flow	-35918000	Operating Cash Flow: -35759000 Open source Capital Expenditure: 159000 Open source
20252025-12-31	Free cash flow	-52994000	Operating Cash Flow: -52432000 Open source Capital Expenditure: 562000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

121% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	177.1%	Total Liabilities: 111381000 Open source Total Assets: 62884000 Open source
20212021-12-31	Liabilities / assets	232.5%	Total Liabilities: 144127000 Open source Total Assets: 61993000 Open source
20222022-12-31	Liabilities / assets	307.7%	Total Liabilities: 175624000 Open source Total Assets: 57070000 Open source
20232023-12-31	Liabilities / assets	285.5%	Total Liabilities: 163905000 Open source Total Assets: 57418000 Open source
20242024-12-31	Liabilities / assets	159.3%	Total Liabilities: 161580000 Open source Total Assets: 101424000 Open source
20252025-12-31	Liabilities / assets	121%	Total Liabilities: 194087000 Open source Total Assets: 160425000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.14× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	2.11×	Current Assets: 44625000 Open source Current Liabilities: 21104000 Open source
20212021-12-31	Current assets / current liabilities	2.15×	Current Assets: 47259000 Open source Current Liabilities: 21964000 Open source
20222022-12-31	Current assets / current liabilities	1.01×	Current Assets: 39888000 Open source Current Liabilities: 39528000 Open source
20232023-12-31	Current assets / current liabilities	2.24×	Current Assets: 40966000 Open source Current Liabilities: 18308000 Open source
20242024-12-31	Current assets / current liabilities	4.68×	Current Assets: 88220000 Open source Current Liabilities: 18865000 Open source
20252025-12-31	Current assets / current liabilities	3.14×	Current Assets: 149269000 Open source Current Liabilities: 47608000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−USD 55.78 million Exact value Exact value: -55783000 USD 2020-01-01 – 2020-12-31: -55783000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aquestive Therapeutics, Inc. · 2020-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Net Income: -55783000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -55783000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828022005393/aqst-20211231.htm#1727798 Filing: 000162828022005393 The citation records this snapshot. The page link may show a newer release later.	−USD 45.46 million Exact value Exact value: -45459000 USD 2020-01-01 – 2020-12-31: -45459000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aquestive Therapeutics, Inc. · 2020-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Operating Cash Flow: -45459000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -45459000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828022005393/aqst-20211231.htm#1263506 Filing: 000162828022005393 The citation records this snapshot. The page link may show a newer release later.	USD 517,000 Exact value Exact value: 517000 USD 2020-01-01 – 2020-12-31: 517000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aquestive Therapeutics, Inc. · 2020-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Capital Expenditure: 517000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 517000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828022005393/aqst-20211231.htm#1266241 Filing: 000162828022005393 The citation records this snapshot. The page link may show a newer release later.	−USD 45.98 million Calculation and evidence -45459000 − 517000 USD Exact free cash flow: -45976000 USD 2020-01-01 – 2020-12-31: -45459000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 517000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aquestive Therapeutics, Inc. · 2020-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Free cash flow: -45976000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -45459000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828022005393/aqst-20211231.htm#1263506 Filing: 000162828022005393 Input fundies:CapitalExpenditure: 517000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828022005393/aqst-20211231.htm#1266241 Filing: 000162828022005393 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 70.54 million Exact value Exact value: -70539000 USD 2021-01-01 – 2021-12-31: -70539000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aquestive Therapeutics, Inc. · 2021-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Net Income: -70539000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -70539000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828023010180/aqst-20221231.htm#1596848 Filing: 000162828023010180 The citation records this snapshot. The page link may show a newer release later.	−USD 32.98 million Exact value Exact value: -32979000 USD 2021-01-01 – 2021-12-31: -32979000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aquestive Therapeutics, Inc. · 2021-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Operating Cash Flow: -32979000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -32979000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828023010180/aqst-20221231.htm#1235391 Filing: 000162828023010180 The citation records this snapshot. The page link may show a newer release later.	USD 913,000 Exact value Exact value: 913000 USD 2021-01-01 – 2021-12-31: 913000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aquestive Therapeutics, Inc. · 2021-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Capital Expenditure: 913000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 913000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828023010180/aqst-20221231.htm#1237511 Filing: 000162828023010180 The citation records this snapshot. The page link may show a newer release later.	−USD 33.89 million Calculation and evidence -32979000 − 913000 USD Exact free cash flow: -33892000 USD 2021-01-01 – 2021-12-31: -32979000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 913000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aquestive Therapeutics, Inc. · 2021-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Free cash flow: -33892000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -32979000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828023010180/aqst-20221231.htm#1235391 Filing: 000162828023010180 Input fundies:CapitalExpenditure: 913000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828023010180/aqst-20221231.htm#1237511 Filing: 000162828023010180 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 54.41 million Exact value Exact value: -54410000 USD 2022-01-01 – 2022-12-31: -54410000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aquestive Therapeutics, Inc. · 2022-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Net Income: -54410000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -54410000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828024009010/aqst-20231231.htm#1773377 Filing: 000162828024009010 The citation records this snapshot. The page link may show a newer release later.	−USD 9.82 million Exact value Exact value: -9819000 USD 2022-01-01 – 2022-12-31: -9819000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aquestive Therapeutics, Inc. · 2022-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Operating Cash Flow: -9819000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9819000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828024009010/aqst-20231231.htm#1330362 Filing: 000162828024009010 The citation records this snapshot. The page link may show a newer release later.	USD 1.02 million Exact value Exact value: 1024000 USD 2022-01-01 – 2022-12-31: 1024000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aquestive Therapeutics, Inc. · 2022-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Capital Expenditure: 1024000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1024000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828024009010/aqst-20231231.htm#1332246 Filing: 000162828024009010 The citation records this snapshot. The page link may show a newer release later.	−USD 10.84 million Calculation and evidence -9819000 − 1024000 USD Exact free cash flow: -10843000 USD 2022-01-01 – 2022-12-31: -9819000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 1024000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aquestive Therapeutics, Inc. · 2022-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Free cash flow: -10843000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9819000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828024009010/aqst-20231231.htm#1330362 Filing: 000162828024009010 Input fundies:CapitalExpenditure: 1024000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828024009010/aqst-20231231.htm#1332246 Filing: 000162828024009010 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 7.87 million Exact value Exact value: -7870000 USD 2023-01-01 – 2023-12-31: -7870000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aquestive Therapeutics, Inc. · 2023-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Net Income: -7870000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7870000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828025010506/aqst-20241231.htm#1855670 Filing: 000162828025010506 The citation records this snapshot. The page link may show a newer release later.	−USD 6.38 million Exact value Exact value: -6380000 USD 2023-01-01 – 2023-12-31: -6380000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aquestive Therapeutics, Inc. · 2023-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Operating Cash Flow: -6380000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6380000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828025010506/aqst-20241231.htm#1361515 Filing: 000162828025010506 The citation records this snapshot. The page link may show a newer release later.	USD 995,000 Exact value Exact value: 995000 USD 2023-01-01 – 2023-12-31: 995000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aquestive Therapeutics, Inc. · 2023-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Capital Expenditure: 995000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 995000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828025010506/aqst-20241231.htm#1363400 Filing: 000162828025010506 The citation records this snapshot. The page link may show a newer release later.	−USD 7.38 million Calculation and evidence -6380000 − 995000 USD Exact free cash flow: -7375000 USD 2023-01-01 – 2023-12-31: -6380000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 995000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aquestive Therapeutics, Inc. · 2023-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Free cash flow: -7375000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6380000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828025010506/aqst-20241231.htm#1361515 Filing: 000162828025010506 Input fundies:CapitalExpenditure: 995000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000162828025010506/aqst-20241231.htm#1363400 Filing: 000162828025010506 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 44.14 million Exact value Exact value: -44137000 USD 2024-01-01 – 2024-12-31: -44137000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aquestive Therapeutics, Inc. · 2024-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Net Income: -44137000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -44137000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm#1809028 Filing: 000139873326000018 The citation records this snapshot. The page link may show a newer release later.	−USD 35.76 million Exact value Exact value: -35759000 USD 2024-01-01 – 2024-12-31: -35759000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aquestive Therapeutics, Inc. · 2024-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Operating Cash Flow: -35759000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35759000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm#1351691 Filing: 000139873326000018 The citation records this snapshot. The page link may show a newer release later.	USD 159,000 Exact value Exact value: 159000 USD 2024-01-01 – 2024-12-31: 159000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aquestive Therapeutics, Inc. · 2024-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Capital Expenditure: 159000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 159000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm#1353553 Filing: 000139873326000018 The citation records this snapshot. The page link may show a newer release later.	−USD 35.92 million Calculation and evidence -35759000 − 159000 USD Exact free cash flow: -35918000 USD 2024-01-01 – 2024-12-31: -35759000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 159000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aquestive Therapeutics, Inc. · 2024-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Free cash flow: -35918000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -35759000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm#1351691 Filing: 000139873326000018 Input fundies:CapitalExpenditure: 159000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm#1353553 Filing: 000139873326000018 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 83.78 million Exact value Exact value: -83784000 USD 2025-01-01 – 2025-12-31: -83784000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Aquestive Therapeutics, Inc. · 2025-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Net Income: -83784000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -83784000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm#1808255 Filing: 000139873326000018 The citation records this snapshot. The page link may show a newer release later.	−USD 52.43 million Exact value Exact value: -52432000 USD 2025-01-01 – 2025-12-31: -52432000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Aquestive Therapeutics, Inc. · 2025-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Operating Cash Flow: -52432000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -52432000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm#1351039 Filing: 000139873326000018 The citation records this snapshot. The page link may show a newer release later.	USD 562,000 Exact value Exact value: 562000 USD 2025-01-01 – 2025-12-31: 562000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Aquestive Therapeutics, Inc. · 2025-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Capital Expenditure: 562000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 562000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm#1352994 Filing: 000139873326000018 The citation records this snapshot. The page link may show a newer release later.	−USD 52.99 million Calculation and evidence -52432000 − 562000 USD Exact free cash flow: -52994000 USD 2025-01-01 – 2025-12-31: -52432000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 562000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Aquestive Therapeutics, Inc. · 2025-12-31 Aquestive Therapeutics, Inc. (edgar:1398733) Free cash flow: -52994000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:13:20Z Snapshot: c3292f339ee375b2e7d36171689b84b7caaeac734284924c38a41ddbd71cfbb8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1398733?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -52432000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm#1351039 Filing: 000139873326000018 Input fundies:CapitalExpenditure: 562000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm#1352994 Filing: 000139873326000018 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

112 filings · 3,086 latest values · 3,086 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001398733, 1398733, AQST, edgar:1398733

Also known as Aquestive Therapeutics, Inc., MonoSol Rx, Inc.

Aquestive Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation